Lupus & antiphospholipid syndrome
Clinical algorithm model based on cell-free DNA (cfDNA) to predict systemic lupus erythematosus (SLE) disease activity
Authors' conclusion
Through systematic stratified analysis and clinical algorithm model, this study found that plasma cfDNA concentration is closely related to SLE disease severity
Study context
- Population
- Patients with active and inactive SLE (plasma samples)
- Participants
- 88 vs 39
- Exposure
- Active SLE vs inactive SLE
- Active SLEn = 88
- Inactive SLEn = 39reference
- Outcome
- Plasma cfDNA concentration
Methodological detailsclinical algorithm model
- Clinical algorithm model
Main finding
As reported in the abstract
P = 0.043
Observational data: associations, not effects.
Further findings
cfDNA fragment length distribution
- cfDNA fragments enriched in the ranges of 153-198 bp and 300-599 bp
Correlation of cfDNA concentration with anti-dsDNA antibody titer reduction
- R
- −0.301
- p
- P = 0.034
Autoantibodies possibly associated with variation of cfDNA concentration
- anti-U1 ribonucleoprotein
- P = 0.012
- anti-Sjogren syndrome A
- P = 0.024
- anti-dsDNA
- P = 0.0208
- Anti-nucleosome antibodies
- P = 0.0382
cfDNA concentration by renal damage in active SLE (reduced cfDNA associated with renal damage)
- Renal damage vs no renal damage (presumed order as printed), ng/µL
- 0.31 [0.11-0.73] vs 0.65 [0.27-1.53]
- p
- P = 0.009
Active index (cfDNA concentration plus other clinical indices) for distinguishing active SLE
- AUC
- 0.886
Correlation of Active index with SLE disease activity index score
- R
- 0.6724
- p
- P < 0.0001
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →